Adaptive Biotechnologies: Why Insider Selling Casts a Shadow on Its High-Flying Stock

Related Articles

Is Insider Selling a Red Flag for Adaptive Biotechnologies (ADPT) Investors

7 months ago

Insider Selling Casts a Shadow on PubMatic's AI-Driven Growth Story

3 months ago

The Shadow of Insider Selling

3 months ago

AIAI Holdings: Insider Selling Casts a Shadow Over Its AI Ambitions

3 months ago

Category

You may also like

Stock News•1 day ago

Adaptive Biotechnologies: Getting Paid Every Step Of The Way To A Myeloma Cure

Adaptive Biotechnologies' MRD revenues rose 33% YoY to $66.2M, with clinical ASP up 7% and test volumes up 43%, after new NCCN guidelines and IMS cure definitions positioned clonoSEQ as the standard f...

ADPT

Share

Stock News•3 weeks ago

Adaptive Biotechnologies (NASDAQ:ADPT) Hits New 52-Week High – Still a Buy?

Adaptive Biotechnologies (NASDAQ:ADPT) hit a new 52-week high of $30.10 on Tuesday, up from a prior close of $29.84, on light volume of 2,895 shares. Several research firms have recently commented on ...

ADPT

Share

Stock News•3 months ago

An Adaptive Biotechnologies Insider Sold $8.5 Million in Stock After an 85% Run

An Adaptive Biotechnologies insider sold ~386K shares for $8.5M on July 2, 2026, after the stock's 85% run-up.

ADPT

Share